Health
Here’s a rapid-fire update on all 36 stocks in the Club’s portfolio, including 2 recent buys
During the Investing Club’s August Monthly Meeting, Jim Cramer provided his latest thinking on all 36 names in his Charitable Trust. Source
Read More
These are the top 5 performing Club stocks from mid-July to our August Monthly Meeting
Since the CNBC Investing Club’s July Monthly Meeting, the stock market has seesawed up and then down on a slew of quarterly earnings results and inflation data. That’s left Wall Street struggling this month. Here’s a look at the best performers from the Club’s 36 holdings from the market close after the July 12 meeting […]
Read More
CVS stock plunges after Blue Shield of California drops retailer’s pharmacy services to save on drug costs
A CVS location in New York, US, on Thursday, Feb. 9, 2023. Stephanie Keith | Bloomberg | Getty Images Shares of CVS Health plunged 9% on Thursday after Blue Shield of California said it will drop the company’s pharmacy benefit management services and instead partner with Mark Cuban’s Cost Plus Drugs company and Amazon Pharmacy […]
Read More
Blue Shield of California taps Amazon, Mark Cuban’s Cost Plus Drugs for its pharmacy network
Source: Blue Shield of California Blue Shield of California is teaming up with Mark Cuban’s Cost Plus Drug Company and Amazon Pharmacy — turning away from traditional drug store chains and ditching in part health giant CVS — in a move to save on drug costs for its 4.8 million members. The CEO of the […]
Read More
JPMorgan upgrades this eye care stock that can deliver consistent growth
Investors looking for consistency should turn to Alcon , JPMorgan said. The bank upgraded the eye care stock to overweight from neutral on Thursday. It also raised its price target to $89.30 per share from $79.80. JPMorgan’s forecast implies roughly 11% upside from Wednesday’s $80.24 close. JPMorgan’s call comes after Alcon — which makes Opti-Free […]
Read More
Wegovy could prevent up to 1.5 million heart attacks, strokes over 10 years, study says
A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023. Jim Vondruska | Reuters Novo Nordisk’s blockbuster weight loss injection Wegovy could prevent up to 1.5 million heart attacks, strokes and other cardiovascular events in the U.S. over 10 years, according to […]
Read More
Hawaii governor warns developers against predatory land buying in devastated Lahaina
A general view shows damage in the fire ravaged town of Lahaina on the island of Maui in Hawaii, U.S., August 15, 2023. Mike Blake | Reuters Hawaii Gov. Josh Green is warning developers from the mainland United States and around the world not to buy up land in the wake of catastrophic wildfires that […]
Read More
Appeals court imposes restrictions on abortion pill, but drug will stay on the market for now
A container holding boxes of Mifepristone, the first medication in a medical abortion, are prepared for patients at Alamo Women’s Clinic in Carbondale, Illinois, April 20, 2023. Evelyn Hockstein | Reuters A federal appeals court on Wednesday imposed restrictions on the abortion pill mifepristone, though the ruling will not have an immediate impact. The order […]
Read More
Activists ease up on Salesforce — plus, 10 other Club stocks traded by Wall Street pros
The extraordinary activist-investor interest in Salesforce (CRM) eased further in the second quarter, according to the latest regulatory filings from influential Wall Street pros. These big-name investors also made moves in nine other Club stocks during a strong three-month stretch that ended the best first half for the market in years. Starting with Salesforce, Dan […]
Read More
GE HealthCare can surge more than 25% as it capitalizes on key Alzheimer’s opportunity, Wells Fargo says
Wells Fargo is confident GE HealthCare can benefit from the growth of a key Alzheimer’s drug. The firm initiated coverage of the medical device provider with an overweight rating and a $90 per share price target. Wells’ forecast implies nearly 28% upside from Tuesday’s $70.54 close. Analyst Larry Biegelsen highlighted the growth of Alzheimer’s drug […]
Read More